Brokerages forecast that Dyadic International, Inc. (NASDAQ:DYAI) will post $610,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Dyadic International’s earnings, with the highest sales estimate coming in at $800,000.00 and the lowest estimate coming in at $410,000.00. Dyadic International reported sales of $420,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 45.2%. The company is scheduled to report its next earnings results on Thursday, November 11th.
According to Zacks, analysts expect that Dyadic International will report full-year sales of $2.32 million for the current financial year, with estimates ranging from $1.63 million to $3.00 million. For the next fiscal year, analysts forecast that the business will report sales of $8.67 million, with estimates ranging from $3.30 million to $14.03 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Dyadic International.
Dyadic International (NASDAQ:DYAI) last issued its earnings results on Thursday, August 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05). Dyadic International had a negative net margin of 536.88% and a negative return on equity of 43.25%.
Several large investors have recently made changes to their positions in DYAI. UBS Group AG boosted its holdings in Dyadic International by 41.8% during the first quarter. UBS Group AG now owns 9,395 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,769 shares during the last quarter. Royal Bank of Canada boosted its holdings in Dyadic International by 77.9% during the second quarter. Royal Bank of Canada now owns 6,969 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,051 shares during the last quarter. Forefront Analytics LLC boosted its holdings in Dyadic International by 24.7% during the first quarter. Forefront Analytics LLC now owns 29,210 shares of the biotechnology company’s stock worth $161,000 after buying an additional 5,794 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Dyadic International by 15.2% during the second quarter. JPMorgan Chase & Co. now owns 54,184 shares of the biotechnology company’s stock worth $194,000 after buying an additional 7,165 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Dyadic International by 71.9% during the first quarter. Barclays PLC now owns 23,669 shares of the biotechnology company’s stock worth $129,000 after buying an additional 9,896 shares during the last quarter. Institutional investors own 14.44% of the company’s stock.
NASDAQ:DYAI traded up $0.10 during mid-day trading on Tuesday, reaching $5.37. The stock had a trading volume of 661,650 shares, compared to its average volume of 1,668,283. The business’s 50 day moving average is $4.65 and its 200 day moving average is $4.47. Dyadic International has a fifty-two week low of $3.15 and a fifty-two week high of $8.78.
Dyadic International Company Profile
Dyadic International, Inc engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines.
Read More: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.